Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
LH — frequently asked questions
Is Labcorp Holdings Inc. overvalued?
In our latest published analysis dated 2026-10-07, LH looks meaningfully overvalued. The price recorded at analysis is 312 USD versus our fair value of 264 USD; the high endpoint is presented separately as potential value of 335 USD. That implies roughly 15.3% downside to fair value at that date.
Our latest published report, analyzed 2026-10-07, gives LH a fair value of 264 USD and a potential value of 335 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Labcorp Holdings Inc.'s archetype; it is a dated research output, not a live price.
Should I buy LH now?
Our latest published rating for LH, analyzed 2026-10-07, is Reduce. Labcorp Holdings Inc. looks meaningfully overvalued at the analysis-date price of 312 USD versus fair value of 264 USD; potential value is 335 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for LH?
The dedicated bear-case section in our report analyzed 2026-10-07 documents Labcorp Holdings Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is LH's rating?
Our latest published rating for LH, analyzed 2026-10-07, is Reduce, with a published moat assessment of 7.2/10 (Narrow). It reflects our fair value of 264 USD, the potential value of 335 USD, and the price recorded at analysis (312 USD).
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.
§1 Resumen ejecutivoEN
Respuesta en 30 segundosReduce
Precio frente a valor
Precio
$311.71
Valor razonable
$263.85
Valor potencial
$335.23
A fecha de
2026-10-06
Por qué puede funcionar
The largest upside opportunity for Labcorp is accelerating the clinical adoption of high-complexity specialty testing in oncology, neurology, and autoimmune disease, combined with double-digit growth in direct-to-consumer testing through Labcorp OnDemand.
Qué cambiaría nuestra opinión
Diagnostics segment operating margin falls below 13.5% within 12 months following statutory implementation of PAMA Medicare fee schedule reductions and commercial managed-care reimbursement compression.
We issue a Reduce rating on Labcorp Holdings Inc. as its share price of $311.71 as of October 6, 2026 trades at an 18.1% premium to our intrinsic Fair value of $263.85, presenting an asymmetric negative risk-reward profile with -15.4% implied downside.
Our house rating on Labcorp Holdings Inc. is Reduce. For an ordinary investor, this recommendation indicates that current share prices overvalue the firm's fundamental compounding trajectory, meaning capital is better deployed elsewhere; existing shareholders should trim position sizes to underweight or neutral, as future total returns over the next 12 to 18 months are expected to trail baseline market hurdles.
As of October 6, 2026, Labcorp common stock trades at $311.71 per share, which sits at an 18.1% premium to our intrinsic Fair value midpoint of $263.85 per share and implies -15.4% downside. Even when measured against our Potential value ceiling of $335.23 per share—which models aggressive expansion in high-complexity specialty testing and sustained biopharma —the stock offers only an uncompelling 7.5% upside ceiling, providing inadequate risk buffer against structural regulatory fee cuts.
The critical risk that would further impair our valuation is statutory reimbursement enforcement under the Protecting Access to Medicare Act (PAMA) combined with commercial managed-care fee compression. If statutory PAMA fee schedule reductions take full effect across the Diagnostics segment ($10,876.5 million in FY2025 revenue), Diagnostics operating margins would decline from 16.36% toward 13.5%. Investors would observe this deterioration through Diagnostics average revenue per requisition falling by more than 2.0% annually, compressing consolidated operating margins by approximately 300 basis points and driving an estimated 18.5% impairment to intrinsic fair value.7
Conversely, the principal operational engine that could support business performance toward our Potential value of $335.23 is an accelerating mix shift toward high-margin esoteric testing in oncology, autoimmune disease, and neurology, accompanied by double-digit volume growth in direct-to-consumer testing through Labcorp OnDemand. As specialized testing expands within the clinical requisition mix and Biopharma Laboratory Services maintains operating leverage (segment margin up 130 basis points in Q2 2026), consolidated operating margins would expand from 9.92% in FY2025 toward 11.66% by FY2030. This would generate over $1.38 billion in annual free cash flow, powering continued share repurchases and per-share compounding, though this optimistic thesis remains strictly secondary to current valuation excess.4
Diagnostics Logistics Density and Hospital Reference Integration
Extensive patient service center footprint and courier logistics density across $10,876.5M in Diagnostics revenue lower per-sample transport costs and anchor health system partnerships.
Specialty Testing Mix and Consumer Digital Direct Channels
Mix shift toward proprietary oncology, neurology, and autoimmune panels alongside upfront-paid Labcorp OnDemand testing expands gross margins and eliminates bad debt.
Biopharma Clinical Trial Contract Stability
Multi-year central laboratory trial management agreements insulate BLS from life science instrumentation capex cycles, driving 130 bps of segment margin expansion in Q2 2026.4
Recomendación de la casa
We assign a Reduce rating to Labcorp Holdings Inc. because the current share price of $311.71 trades at an 18.1% premium to our intrinsic Fair value of $263.85, offering an unattractive -15.4% implied return while facing looming Medicare PAMA reimbursement cuts.
Descripción general de la empresa
Labcorp Holdings Inc. (NYSE: LH) is a leading global healthcare diagnostics and life sciences compounder operating through two primary business engines: Diagnostics Laboratories and Biopharma Laboratory Services. The company serves a diverse client base comprising individual patients, physicians, hospitals, health systems, employers, and global biopharmaceutical sponsors.
The Diagnostics segment generated $10,876.5 million in FY2025 revenue (78.0% of total revenue) and $1,779.9 million in operating income. Diagnostics provides routine clinical blood tests, specialized pathology, and advanced biomarker testing in oncology, neurology, women's health, and autoimmune diseases, supported by an extensive nationwide network of patient service centers and entrenched regional hospital reference partnerships.
The Biopharma Laboratory Services (BLS) segment generated $3,098.2 million in FY2025 revenue (22.0% of total revenue) and $498.5 million in operating income. BLS provides specialized central laboratory testing, trial management, and early-stage drug development assay services to global clinical trial sponsors across multi-year contracts, diversifying the company away from routine clinical testing cycles.
§2 Caso bajistaEN
Under a severe compound stress test, Labcorp faces converging headwinds across its primary operating segments. Full implementation of statutory Medicare PAMA cuts combined with commercial payer contract compression across $10,876.5M in Diagnostics revenue reduces segment operating margins by 300 basis points toward 13.5%. Simultaneously, deepening capital constraints among emerging biotechnology sponsors prolong flat pricing in Early Development and cause Central Labs clinical trial cancellations, lowering 5-year top-line compound growth by 5 percentage points. Compounding operational deleverage, refinancing $1.78B in maturing debt tranches out of $7,204.0M in total debt amidst persistent inflation pushes the cost of capital up by 200 basis points above the computed 8.0711% baseline. This operational and financial shock contracts annual free cash flow significantly below the FY2025 baseline of $1,206.0M, forcing multiple compression from the current forward P/E of 16.16x toward 13.2x and illustrating the vulnerability of current share prices ($311.71) to structural reimbursement and macroeconomic shocks.
In the bear case scenario, full enforcement of Medicare PAMA fee cuts and aggressive commercial payer fee compression reduce Diagnostics operating margins toward 13.5%. Simultaneously, persistent biopharma R&D spending constraints result in flat pricing and trial cancellations in Early Development, while refinancing $1.78B of maturing debt increases debt service costs. This compresses operating cash flows and triggers valuation multiple de-rating.
Cómo puede fallar esta tesis
PAMA Reimbursement Enforcement and Payer Fee Schedule Compression
Full implementation of PAMA statutory cuts and commercial payer reimbursement compression on $10,876.5M of Diagnostics revenue drops segment operating margin from 16.36% to below 13.5%, reducing group operating margin by approximately 300 bps.4,7
FV impact
-5.5%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Señales de alerta temprana a vigilar
Los cinco acontecimientos que debilitarían nuestra tesis de inversión.
01
Diagnostics Organic Volume Growth
Volume growth slipping below 1.5% signals courier network underutilization and loss of health system outpatient testing share, impairing fixed-cost absorption.
Segment margin expansion slowing to 50 bps or below demonstrates that flat Early Development pricing is overwhelming Central Labs , requiring a downward revision to consolidated earnings power.
§3 Foso competitivoEN
Narrow
Labcorp's Narrow Moat rating is underpinned by its entrenched specimen collection logistics and courier route density across the United States. In FY2025, the Diagnostics segment generated $10,876.5 million in revenue and $1,779.9 million in operating profit. Operating an extensive infrastructure of patient service centers and automated testing hubs allows Labcorp to achieve fixed-cost absorption that local and regional clinical laboratories cannot replicate. In the second quarter of 2026, Diagnostics delivered 5.5% top-line expansion with 3.6% organic revenue growth and 3.0% volume growth, underscoring the resilience of outpatient testing volumes across hospital reference partnerships.
Beyond routine clinical chemistry, Biopharma Laboratory Services provides a secondary source of competitive advantage anchored in customer switching costs. BLS produced $3,098.2 million in FY2025 revenue, managing multi-year clinical trial testing protocols through its central laboratories. Once a biopharmaceutical sponsor standardizes biomarker assays, patient stratification methodologies, and global trial logistics on Labcorp's platform, transferring the protocol mid-trial introduces substantial regulatory risk and operational delays. This structural lock-in allowed BLS to expand segment operating margins by 130 basis points year-over-year in Q2 2026, outpacing Diagnostics margin expansion.
Despite these formidable structural moats, Labcorp is constrained from earning a Wide Moat designation due to statutory reimbursement risks. The routine testing business faces periodic rate updates under the Protecting Access to Medicare Act (PAMA) alongside aggressive fee compression from commercial payers. In Q2 2026, payer cohort headwinds shaved 20 to 30 basis points from diagnostic testing volume. While high-complexity testing in oncology and neurology and upfront-paid consumer testing through Labcorp OnDemand partially insulate profit margins, the lack of unilateral pricing power over routine fee schedules caps the competitive advantage duration at a 10-year horizon.
Beneficio económico
Labcorp generates sustained economic profit above its cost of capital. Calculated ROIC of 8.41% exceeds the computed WACC of 8.0711%. In FY2025, the company generated $1,384.7M in operating income and $1,206.0M in free cash flow on revenue of $13,951.7M. However, because routine clinical testing is subject to periodic statutory Medicare reimbursement cuts and commercial payer fee compression, economic profits cannot be protected with high certainty beyond a 10-year horizon, supporting a Narrow rather than Wide Moat designation.2,5,6
7.2/ 10
Narrow
Sources of advantage
01Cost Advantage (Scale and Specimen Logistics Route Density) — Diagnostics generated $10,876.5M in FY2025 revenue and delivered 5.5% revenue growth in Q2 2026 with 3.6% organic growth and 3.0% volume growth. Immense route density across regional patient service centers and hospital reference partnerships minimizes specimen transportation and handling costs per requisition, creating an insurmountable cost advantage over regional and hospital laboratories.Wide
02Switching Costs (Clinical Trial Protocols and Central Laboratory Infrastructure) — Biopharma Laboratory Services generated $3,098.2M in FY2025 revenue and expanded by 130 basis points in Q2 2026. Standardizing multi-year global clinical trials on Labcorp's validated assay platforms and investigator database creates high switching costs for pharmaceutical sponsors during active regulatory trials.
Amenazas conocidas al foso
Amenaza
Severidad
Cronograma
Mitigación
Reimbursement Cuts Under PAMA and Commercial Payer Fee Schedule Compressions
high
12 to 24 months
Expanding higher-margin specialized oncology and companion diagnostic testing, automating specimen processing, and securing reference laboratory partnerships with health systems.4
The highlighted cell is Fair value when every assumption sits at its base level ($263.85). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.0B after modeled reinvestment of $177.9M, with terminal value at 79.4% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
In the base case modal path, Labcorp compounds revenue at 5.72% in FY2026 ($14,749.3M) and 4.95% in FY2027 ($15,479.5M), before tapering toward 4.2% across the forecast horizon. Consolidated operating margin expands moderately from 9.92% in FY2025 to 10.44% in FY2026 and 11.66% by FY2030. High free cash flow conversion ($1,206.0M in FY2025) supports ongoing share repurchases and debt service, yielding an intrinsic fair value of $263.85.1,5,6
Upgrade the rating; Verify the organic persistence of volume gains and examine whether clinical trial booking momentum in central laboratories is sustained before considering any portfolio reallocation.
Disparador: Consolidated revenue growth accelerating above the upper boundary of management annual guidance, accompanied by Diagnostics organic volume expansion and Biopharma Laboratory Services operating margin expansion substantially exceeding baseline expectations.
A pronounced operational beat driven by rapid specialty diagnostic test adoption and sustained clinical trial demand would demonstrate that operational efficiencies and volume leverage are overcoming statutory reimbursement headwinds, lifting intrinsic value closer to $311.71.
En línea
Maintain Reduce; Maintain position discipline by trimming existing holdings opportunistically on market strength and monitoring upcoming payer fee schedule updates.
Disparador: Consolidated revenue and earnings tracking within management full-year guided ranges, with routine testing volume growth and segment margin expansion matching baseline consensus expectations.
Matching established guidance confirms that the business is compounding steadily but fails to bridge the valuation gap between $311.71 and intrinsic value $263.85, preserving an unfavorable implied return of -15.4%.
Fallo
Downgrade the rating; Accelerate portfolio trimming and reallocate proceeds into higher-conviction opportunities with favorable risk-reward profiles until laboratory volume and reimbursement stabilization emerge.
Disparador: Consolidated revenue decelerating below the lower bound of annual guidance, caused by volume contraction from commercial payer pushback or prolonged biopharma clinical trial cancellations.
An operational shortfall would indicate that statutory rate cuts and payer contract pressure are eroding core laboratory profitability while biopharma spending retrenchment impairs high-margin testing, accelerating downside toward stressed valuation levels.
Calidad de los beneficios
Earnings quality is solid, characterized by operating cash generation and free cash flow that consistently surpass reported net income. Cash conversion remains high due to disciplined working capital management, moderate capital expenditure requirements, and minimal bad debt expense supported by upfront consumer digital payments. Fixed-cost absorption across centralized testing hubs and stable depreciation charges ensure that reported operating income accurately reflects underlying economic profit without reliance on aggressive revenue recognition or non-cash accounting adjustments.
Evolución de las estimaciones
Consensus earnings and revenue revisions have moved upward across forward fiscal periods following resilient operating performance in both routine diagnostics and biopharma laboratory services. While analysts have raised near-term projections to reflect operational cost actions, the share price at $311.71 continues to reflect an excessive premium over intrinsic value $263.85, leaving the risk-reward profile unfavorable.
Diagnostic test volume demonstrates route density fixed-cost absorption and hospital system reference partnership demand, driving core operating leverage.
02
Métrica:
Biopharma Laboratory Services Margin Expansion
ActualOutpacing routine testing margin growth due to operational restructuring and central laboratory study execution.
Cash flow generation represents Labcorp's primary financial strength. In FY2025, the company delivered $1,640.5M in cash from operations and incurred $434.5M in capital expenditures, generating $1,206.0M in free cash flow. Free cash flow conversion relative to GAAP net income of $876.5M was exceptional at 137.6%, reflecting low working capital intensity and non-cash depreciation charges of $681.1M. In the second quarter of 2026, cash generation remained durable, producing $445.5M in operating cash flow and $313.9M in free cash flow after $131.6M in capital investments.5,6
The trajectory of return on invested capital is improving as laboratory operating margins recover from post-pandemic normalizations. In FY2025, operating income of $1,384.7M on revenue of $13,951.7M yielded an operating margin of 9.92%. With FY2026 operating margins modeled at 10.44% and expanding toward 11.66% by FY2030, supported by 130 bps margin expansion in Biopharma Laboratory Services, returns on capital should expand further above the 8.0711% cost of capital benchmark.
Latest calculated ROIC of 8.41% exceeds the computed WACC of 8.0711% by approximately 34 basis points, generating positive economic profit.
Ingresos más recientes14 mil M US$CAGR de ingresos +4,3 %
Margen operativo9,9 %10 periodos fiscales
Flujo de caja libre más reciente1206 M US$FY2025
Deuda neta6671,7 M US$FY2025
Desglose de la cuenta de resultadosCómo la escala del negocio se convierte en beneficio declarado.
StockMarketAgent.AI
Ingresos14 mil M US$Coste de ventas−9939,2 M US$Beneficio bruto4012,5 M US$Gastos operativos−2627,8 M US$Beneficio operativo1384,7 M US$Partidas no operativas e impuestos−508,2 M US$Beneficio neto876,5 M US$
Datos del historial financiero
Ingresos
13.951.700.000 US$
Coste de ventas
9.939.200.000 US$
Beneficio bruto
4.012.500.000 US$
Gastos operativos
2.627.800.000 US$
Beneficio operativo
1.384.700.000 US$
Partidas no operativas e impuestos
-508.200.000 US$
Beneficio neto
876.500.000 US$
Resumen del balanceCómo se mantienen y financian los activos declarados en el período seleccionado.
StockMarketAgent.AI
Composición de activosFinanciado por
Activos totales18,4 mil M US$Efectivo532,3 M US$Activos corrientes4020,5 M US$Pasivos totales9756 M US$Pasivos corrientes2823,5 M US$Patrimonio neto8636,7 M US$
Datos del desglose del balance
Activos totales
18.392.700.000 US$
Efectivo
532.300.000 US$
Activos corrientes
4.020.500.000 US$
Pasivos totales
9.756.000.000 US$
Pasivos corrientes
2.823.500.000 US$
Patrimonio neto
8.636.700.000 US$
Puente de flujo de cajaCómo el flujo de caja operativo se convirtió en flujo de caja libre en FY2025.
StockMarketAgent.AI
Conciliación del flujo operativo
Beneficio neto876,5 M US$Depreciación y amortización+681,1 M US$Compensación basada en acciones+125,8 M US$Otros ajustes operativos−42,9 M US$Flujo de caja operativo1640,5 M US$
Conciliación del efectivo inicial al final
Efectivo inicial1518,7 M US$Flujo de caja operativo+1640,5 M US$Flujo de inversión−1194 M US$Flujo de financiación−1457 M US$Efecto del tipo de cambio+24,1 M US$Efectivo final532,3 M US$
1640,5 M US$ − 434,5 M US$Flujo de caja libre 1206 M US$
Datos del puente de flujo de caja
Beneficio neto
876.500.000 US$
Entrada operativa
1.683.400.000 US$
Depreciación y amortización
681.100.000 US$
Compensación basada en acciones
125.800.000 US$
Flujo de caja operativo
1.640.500.000 US$
Salida operativa
42.900.000 US$
Efectivo disponible
3.183.300.000 US$
Efectivo inicial
1.518.700.000 US$
Efecto del tipo de cambio
24.100.000 US$
Salida de inversión
1.194.000.000 US$
Capex
434.500.000 US$
Otras actividades de inversión
759.500.000 US$
Salida de financiación
1.457.000.000 US$
Efectivo final
532.300.000 US$
Flujo de inversión
-1.194.000.000 US$
Flujo de financiación
-1.457.000.000 US$
Ingresos por segmento operativoProporción de los ingresos totales de 2025-12-31.
14 mil M US$Ingresos totales
Ingresos por segmento operativoProporción
Diagnostics10,9 mil M US$78 %+7,2 % interanual
Biopharma Laboratory Services3098,2 M US$22,2 %+6 % interanual
Fuente: SEC EDGAR · Presentado 2026-02-24 · SEC EDGAR
Datos de composición de ingresos: Ingresos por segmento operativo
Ingresos por segmento operativo
Ingresos
Proporción
interanual
Diagnostics
10,9 mil M US$
78 %
7,2 %
Biopharma Laboratory Services
3098,2 M US$
22,2 %
6 %
Ingresos y beneficiosCómo la escala del negocio se convierte en beneficio declarado.
Efectivo y deudaLiquidez disponible frente al endeudamiento total.
Generación de efectivoFlujo de caja operativo frente al flujo de caja libre.
RentabilidadEvolución de los márgenes bruto, operativo y neto.
Datos financieros puntuales utilizados en el análisis del 2026-10-07.
Datos del historial financiero
Período
Ingresos
EBITDA
Beneficio neto
Flujo de caja operativo
Flujo de caja libre
Capex
Depreciación y amortización
Compensación basada en acciones
Recompras de acciones
Dividendos pagados
Emisión neta de deuda
Flujo de inversión
Flujo de financiación
Efectivo inicial
Efectivo final
Efectivo e inversiones
Deuda total
Margen operativo
ROIC
WACC
Diferencial ROIC−WACC
2016-12-31
9552,9 M US$
1809,6 M US$
711,8 M US$
1197,1 M US$
918,2 M US$
278,9 M US$
499,2 M US$
109,6 M US$
43,9 M US$
139,5 M US$
—
-795,7 M US$
-671 M US$
—
433,6 M US$
433,6 M US$
5777,7 M US$
13,3 %
—
4,9 %
—
2017-12-31
10,3 mil M US$
1845,8 M US$
1227,1 M US$
1498,1 M US$
1185,2 M US$
312,9 M US$
533,2 M US$
109,7 M US$
338,1 M US$
3342,2 M US$
—
-2228,7 M US$
593,2 M US$
433,6 M US$
316,6 M US$
316,6 M US$
6696 M US$
12,7 %
—
4,9 %
—
2018-12-31
11,3 mil M US$
2064,6 M US$
883,7 M US$
1305,4 M US$
925,6 M US$
379,8 M US$
552,1 M US$
91,6 M US$
700 M US$
467,2 M US$
—
206,7 M US$
-1389,9 M US$
316,6 M US$
426,8 M US$
426,8 M US$
6000,9 M US$
11,7 %
—
5,2 %
—
2019-12-31
11,6 mil M US$
2116,9 M US$
823,8 M US$
1444,7 M US$
1044,5 M US$
400,2 M US$
577,2 M US$
107 M US$
450 M US$
2395 M US$
—
-1283,1 M US$
-252,7 M US$
426,8 M US$
337,5 M US$
346,6 M US$
6205 M US$
11,5 %
—
4,8 %
—
2020-12-31
14 mil M US$
3251,5 M US$
1556,1 M US$
2135,3 M US$
1753,6 M US$
381,7 M US$
624,7 M US$
111,7 M US$
100 M US$
151,7 M US$
—
-643,2 M US$
-517,4 M US$
337,5 M US$
1320,8 M US$
1393,8 M US$
6756,4 M US$
17,5 %
—
4,8 %
—
2021-12-31
13,1 mil M US$
3676,4 M US$
2377,3 M US$
3109,6 M US$
2688,1 M US$
421,5 M US$
577 M US$
132,9 M US$
1668,5 M US$
1000 M US$
—
-884,6 M US$
-2065,8 M US$
1320,8 M US$
1381,4 M US$
1483,6 M US$
6342,6 M US$
23,2 %
—
5,6 %
—
2022-12-31
11,9 mil M US$
1954,4 M US$
1279,1 M US$
1955,9 M US$
1526,6 M US$
429,3 M US$
537,2 M US$
116,8 M US$
1100 M US$
195,2 M US$
0 US$
-1652,2 M US$
-1322,2 M US$
1472,7 M US$
320,6 M US$
320,6 M US$
6246,4 M US$
12,1 %
—
7,5 %
—
2023-12-31
12,2 mil M US$
1349,4 M US$
418 M US$
1327,7 M US$
874,1 M US$
453,6 M US$
577,3 M US$
128,7 M US$
1000 M US$
254 M US$
-300 M US$
-1171,5 M US$
-59,3 M US$
430 M US$
536,8 M US$
536,8 M US$
5954,2 M US$
6,0 %
—
7,5 %
—
2024-12-31
13 mil M US$
1811,3 M US$
746 M US$
1585,8 M US$
1095,9 M US$
489,9 M US$
643,5 M US$
116,7 M US$
250,1 M US$
243,1 M US$
1000 M US$
-1366,8 M US$
779,9 M US$
536,8 M US$
1518,7 M US$
1518,7 M US$
7272,8 M US$
8,4 %
—
7,9 %
—
2025-12-31
14 mil M US$
2012,7 M US$
876,5 M US$
1640,5 M US$
1206 M US$
434,5 M US$
681,1 M US$
125,8 M US$
450 M US$
240,7 M US$
-1000 M US$
-1194 M US$
-1457 M US$
1518,7 M US$
532,3 M US$
532,3 M US$
7204 M US$
9,9 %
—
6,7 %
—
§9 Comparación de valoración con pares
Valor razonableReport-date price
Labcorp Holdings Inc.LH
Precio / valor razonable
Valor razonable263,85 US$Report-date price311,71 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión63 / 100
IDEXX Laboratories Inc.IDXX
Precio / valor razonable
Valor razonable342,77 US$Report-date price565,45 US$
Fecha de evaluación
Ventaja competitivaWide
Cuadro de mando de inversión67 / 100
Illumina, Inc.ILMN
Precio / valor razonable
Valor razonable119,53 US$Report-date price259,19 US$
Fecha de evaluación
Ventaja competitivaWide
Cuadro de mando de inversión64 / 100
Labcorp Holdings Inc.LH
Precio / valor razonable
Valor razonable263,85 US$Report-date price311,71 US$
Labcorp Holdings Inc. (LH) trades at 16.2x forward earnings against a peer median of 27.9x. Its EV/EBITDA of 13.8x compares with a peer median of 24.8x. The comparison uses 4 peers: IDEXX Laboratories Inc., Illumina Inc., IQVIA Holdings Inc. and Agilent Technologies Inc., as of 2026-10-07.
§10 Industria y cicloEN
Fase del ciclo
Contraction
Industry capital expenditures represent 4.5% of revenue and capex-to-depreciation stands at 0.80x. Following significant pandemic testing capacity additions, laboratory operators have curtailed expansionary capex, operating below accounting depreciation to optimize existing instrumentation and fleet logistics. Beyond these benchmark metrics, industry capacity, supply, and lead-time data are unavailable; thus the cycle view is demand-led and evidence-limited.
Ciclo alcista
In a cyclical upswing, biopharmaceutical venture capital funding accelerates, revitalizing early-stage drug development studies and boosting high-margin Early Development and Central Labs test volumes. Concurrently, health systems under financial pressure increasingly outsource inpatient and outpatient laboratory testing to Labcorp's reference network, driving specimen volume leverage and expanding enterprise operating margins above 11.5%.
Ciclo bajista
In a cyclical downturn, pharmaceutical sponsors scrutinize R&D pipelines, canceling or delaying clinical trials and leaving Early Development pricing flat. Concurrently, commercial health plans tighten prior-authorization protocols and enforce statutory Medicare PAMA cuts, compressing Diagnostics operating margins toward 13.5% and causing operating deleverage across fixed courier logistics networks.
Tendencias seculares
Tendencia
Impacto
Nota
Aging Demographics and Chronic Disease Proliferation
positive
An expanding population over age 65 drives sustained baseline demand for routine wellness testing, diabetes monitoring, cardiovascular screening, and specialized diagnostic testing.
Biopharmaceutical Clinical Trial Complexity and Precision Medicine
positive
The proliferation of targeted oncology therapeutics, cell and gene therapies, and companion diagnostics requires sophisticated global central laboratory testing infrastructure.
Posicionamiento
Labcorp operates with an asset-lean profile relative to industry peers. In FY2025, capital expenditures of $434.5M on revenue of $13,951.7M resulted in a capex-to-revenue ratio of approximately 3.11%, well below the industry benchmark of 4.5%. This efficient footprint enables superior free cash flow conversion ($1,206.0M in FY2025) while hospital reference agreements allow volume expansion without commensurate capital commitments.4,5,6
§11 Gestión de posiciónEN
Tamaño de posición
0-1%
Under the committee Reduce rating, the stock trades at an 18.14% premium to its fair value of $263.85 against a price of $311.71, generating an implied return of -15.35%. Investors should maintain an underweight stance between 0% and 1%, trimming exposure into current strength.3
Riesgo
Active risk management centers on monitoring legislative updates regarding the Protecting Access to Medicare Act (PAMA), commercial payer prior-authorization trends, and biotechnology venture funding conditions. In addition, investors should monitor corporate debt refinancing spreads on $1.78B of maturing debt out of $7,204.0M in total debt amidst prevailing benchmark yields.
Tramos de entrada
Nivel
Acción
Por qué
$235.00 - $245.00
Re-underwriting evaluation point
Represents an approximate 10% discount to fair value ($263.85), where baseline cash generation and route density begin to offer an acceptable margin of safety.
$195.00 - $210.00
Value accumulation band
Tramos de salida
Nivel
Acción
$315.00 - $325.00
Accelerate position reduction
$335.00 - $345.00
Complete position liquidation
Puntos de control trimestrales
Métrica
Umbral
Acción
Diagnostics Organic Volume Growth
< 1.5% year-over-year
Reduce top-line compound growth projections by 150 basis points and accelerate position trimming.
Flatten segment operating leverage assumptions and lower consolidated projections.
§12 Perspectivas de inversoresEN
Value-Focused Perspective
Avoid
Trading at an 18.1% premium to our intrinsic Fair value of $263.85 and a forward P/E of 16.16x, the margin of safety is negative, leaving capital vulnerable to multiple de-rating upon regulatory fee compression.
Institutional Growth Perspective
Avoid
Forward valuation fully prices in FY2026 revenue growthguidance of 5.4% to 6.3%, while flat Early Development pricing and payer cohort headwinds constrain near-term earnings surprise potential.
Income & Capital Preservation Perspective
Hold
Existing long-term income investors benefit from strong cash flow conversion ($1,206.0M free cash flow in FY2025) supporting consistent dividends, but should refrain from allocating fresh capital at current elevated prices.
§14 Recomendación finalEN
Acción
Reducir
We recommend investors reduce exposure to Labcorp Holdings Inc. (LH). As of October 6, 2026, the equity trades at $311.71 per share, representing an 18.1% premium to our intrinsic Fair value of $263.85 per share and offering an unattractive -15.4% implied return.
While Labcorp's route logistics density and $1,206.0 million in annual free cash flow provide defensive baseline support, the prevailing valuation at 16.16x forward earnings leaves no margin of safety against pending Medicare PAMA fee cuts and subdued biopharma early-stage R&D budgets.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-07 · Published 2026-10-07 · Provider-adjusted · cited for 2 figuresCited in Escenarios
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Severe Life Science R&D Retrenchment and Biopharma Trial Cancellations
Deepening biotech capital constraints and trial cancellations cause Early Development and Central Labs volumes to contract, while payer volume headwinds and flat pricing drop group revenue growth by 5 percentage points relative to baseline.4,6
FV impact
-8.7%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 24 months
Refinancing Shock and Macro Cost of Capital Surge
Refinancing $1.78B of maturing debt under $7,204.0M in total debt amidst sticky inflation and wider corporate spreads pushes WACC up by 200 bps from the computed 8.0711% baseline to above 10.07%.2,3
FV impact
-15.9%
Cost of capital 2 points higher
Trigger
Within 18 months
Multiple De-Rating on Regulatory Scrutiny and Terminal Growth Fade
Current forward P/E multiple of 16.16x de-rates by 20% toward 13.2x as legislative fee schedule updates and routine testing maturity restrict long-term compound growth.3,4
Annual net interest expense exceeding $260 million signals that refinancing maturing debt tranches ($1.78B over four years) at elevated yields is severely eroding free cash flow to equity.
Actual:Pre-tax cost of debt 6.13% on $7,204.0M total debt
Contraction in Early Development confirms pharmaceutical sponsor budget retrenchment and early-stage trial cancellations, eliminating segment operating leverage.
Actual:Low single digits with flat pricing in Q2 2026
Alerta si< 0% (negative year-over-year revenue for two consecutive quarters)
03Intangible Assets (Proprietary Specialty Test Menu and Digital Consumer Platform) — Specialty diagnostics in oncology, women's health, autoimmune disease, and neurology expanded Diagnostics margins by 50 basis points in Q2 2026, while Labcorp OnDemand achieved double-digit test volume growth with upfront consumer payment. Proprietary clinical algorithms, specialized pathologist expertise, and direct-to-consumer digital channels insulate high-margin testing panels.Moderate
Biotech Funding Caution and Pharmaceutical R&D Budget Retrenchment
medium
12 to 18 months
Executing operational restructuring in Early Development while focusing commercial efforts on multi-year late-stage Central Labs trial execution.4
Discounted forecast-period cash flows (57,49 US$) plus discounted terminal value (222 US$) minus signed per current share (82,27 US$) equals the 197 US$ lens value shown above. Negative net debt is , so subtracting it raises value.
Biopharma Laboratory Services operating margin expands by more than 150 basis points annually4
Diagnostics organic volume growth sustains at or above 3.5% annually4
Share repurchases continue to retire shares at approximately 0.8% annually
In the bull scenario, high-complexity testing volume accelerates across oncology, women's health, and neurology, while direct-to-consumer testing through Labcorp OnDemand sustains double-digit expansion with upfront payment collection. Biopharma Laboratory Services achieves substantial operating leverage as Central Labs trial volumes expand and Early Development restructuring takes hold. Consolidated operating margins expand toward 11.8% to 12.0%, supporting valuation toward the high end of intrinsic value at $335.23.4
Margin progress in laboratory services reflects central laboratory trial execution and cost discipline, determining whether enterprise profit margins can break out above historical ranges.
03
Métrica:
Medicare Fee Schedule and Reimbursement Rates
ActualUnder legislative scrutiny with potential reimbursement cuts posing a persistent overhang on baseline diagnostic revenue.
Por qué importa
Statutory fee updates dictate unit pricing realization across routine clinical chemistry and immunoassay panels, directly impacting segment gross margins.
04
Métrica:
Specialty Testing Menu Mix Shift
ActualProgressing favorably across oncology, neurology, and autoimmune disease panels following targeted specialty asset integration.
Por qué importa
Higher-complexity oncology and autoimmune panels carry resilient commercial pricing and premium margins that offset routine commodity test fee compression.
Management enforces a disciplined capital allocation hierarchy. Acquisition criteria require targets to be accretive within the first year and return their cost of capital within two to three years. Capital return combines quarterly dividends ($2.88 annualized baseline per share) and ongoing share repurchases, which reduced diluted common shares outstanding to 81.1M as of October 2026 from 83.8M diluted average shares in FY2025. Total balance sheet debt stands at $7,204.0M as of year-end 2025, carrying a pre-tax cost of debt of 6.13%. Over the next four years, approximately $1.78B in debt maturities require refinancing or repayment, which is well supported by more than $1.2B in annual free cash flow.
True owner earnings and economic cash compounding power are significantly higher than GAAP accounting profits indicate, providing self-funding capacity for share repurchases and debt retirement.
Diagnostics Generates Over Three-Quarters of Revenue with Robust Fixed-Cost Absorption
Diagnostics delivered $10,876.5M in revenue (77.96% of consolidated sales) and $1,779.9M in operating income in FY2025, expanding by 5.5% in Q2 2026 with 3.6% organic growth.
Consolidated cash generation depends fundamentally on specimen logistics density and outpatient test volumes, making the firm vulnerable to fee schedule compression on routine testing.
Biopharma Laboratory Services revenue of $3,098.2M generated $498.5M in FY2025 operating income, and expanded segment operating margin by 130 basis points in Q2 2026.
Operating leverage in Central Labs and Early Development restructuring serve as the vital catalyst for lifting consolidated operating margins above 11.0%.
Consistent Share Buybacks Compound Per-Share Value
Shares outstanding contracted from 83.8M diluted average shares in FY2025 to 81.1M shares as of October 2026.
Disciplined share repurchases enhance diluted EPS growth by approximately 80 basis points above net income growth annually across the forecast period.
IQVIA Holdings Inc.IQV
Precio / valor razonable
Valor razonable215,19 US$Report-date price258,21 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión51 / 100
Margen
LH
Labcorp Holdings Inc.
$25.3B
16.2x
1.8x
13.8x
11.7%
—
IDXX
IDEXX Laboratories Inc.
$40.7B
30.8x
8.9x
25.6x
74.2%
35.0%
ILMN
Illumina Inc.
$41.3B
44.8x
9.2x
36.9x
32.3%
21.1%
IQV
IQVIA Holdings Inc.
$42.8B
18.0x
2.5x
18.7x
22.8%
13.0%
A
Agilent Technologies Inc.
$47.7B
25.1x
6.5x
24.1x
21.0%
25.6%
Payer Reimbursement Compression and PAMA Statutory Fee Updates
negative
Ongoing legislative updates to the Medicare Clinical Laboratory Fee Schedule under PAMA and commercial payer contract fee negotiations exert persistent pricing pressure on routine testing requisitions.
Hospital System Laboratory Partnership and Outsourcing Wave
positive
Health systems facing operating margin compression and elevated labor costs increasingly partner with Labcorp or sell reference testing operations, expanding route density.
